Subgroup Analysis of the Occurrence of Secondary Endpoints. by Karl Ingard (22582091)

Subjects:

Pooled effect of the therapeutic effects of negative pressure wound therapy versus conventional wound care for sternal wound infection. by Si He (3236646)

Subjects:

Forest plots of secondary outcomes after negative pressure wound therapy versus conventional wound care for sternal wound infection. by Si He (3236646)

Subjects:

Study flow chart. by Karl Ingard (22582091)

Subjects:

Kaplan-Meier curve of the primary outcome. by Karl Ingard (22582091)

Subjects:

Number of Patients Who Reached the Primary and Secondary Endpoints During Follow-up. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Flow diagram of the studies included in the meta-analysis. by Si He (3236646)

Subjects:

Characteristics of studied included. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Flowchart of the search process. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Mean scores and 95% CI of mental health symptoms, COVID-19 admissions and effect size during follow-up. by A. H. Ayesha Lavell (16734002)

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”